文献速递肿瘤 PET/CT

能否从弥漫大B细胞淋巴瘤基线18F-FDG PET/CT显像中健康组织的摄取和体积获得预后信息

Can we obtain prognostic information from healthy tissue uptake and volume in baseline 18F-FDG PET/CT imaging in diffuse large B-cell lymphoma?
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-08-18

本研究纳入259例新诊断弥漫大B细胞淋巴瘤(DLBCL)患者,分析基线FDG PET/CT中健康组织(脾、肝、肾、肺、脑等)的摄取与体积及肿瘤代谢参数与治疗后2年无进展时间(TTP)的关系。结果发现进展患者脾-血SUVmean比值更高、脑SUVmean和TLG更低、骨骼肌SUVmean更低、肝脏体积更大;但肝脏体积和脾-血SUVmean比值在基于肿瘤特征的模型基础上未显著改善2年TTP预测。

要点

  • 进展患者脾-血SUVmean比值显著更高、脑SUVmean和TLG更低、骨骼肌SUVmean更低、肝脏体积更大。
  • 肝脏体积和脾-血SUVmean比值未显著改善基于肿瘤特征的2年TTP预测模型。
  • 健康组织PET/CT指标与2年TTP相关,但未优于仅用肿瘤特征的模型。

核心结论

  • 健康组织PET/CT指标与DLBCL患者2年TTP显著相关,但相比仅使用肿瘤特征的模型并未改善2年TTP的预测。

研究设计与样本

  • 本研究纳入259例新诊断DLBCL患者,结局为治疗开始后2年TTP。
  • 在低剂量CT上对组织进行自动分割,肿瘤病灶采用半自动分割方法(标准化摄取值≥4)勾画并从组织中减去。
  • 对脾、肝、肾、肺、脑测定SUVmean、组织-血SUVmean比值、体积和总病灶糖酵解(TLG);对脂肪、骨和骨骼肌仅评估SUVmean和SUVmean比值。

主要发现

  • 进展患者脾-血SUVmean比值显著更高,脑SUVmean和TLG更低,骨骼肌SUVmean更低,肝脏体积更大。
  • 肝脏体积和脾-血SUVmean比值在基于基线肿瘤特征的现有逻辑回归模型基础上未显著改善2年TTP预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Diffuse large B-cell lymphoma (DLBCL) patients often experience relapse or progression after treatment, emphasizing the need for better prognostic markers. This study investigated baseline FDG uptake and volume of healthy tissues and tumours, to assess their association with time-to-progression (TTP) in DLBCL. METHODS: This study included 259 newly diagnosed DLBCL patients. Outcome was two-year TTP after treatment initiation. Automatic segmentation of tissues was performed on the low dose CT scans. Tumour lesions were outlined with a semi-automated segmentation method (standardised uptake value ≥ 4) and subtracted from the tissues. Mean standardised uptake value (SUVmean), tissue-to-blood SUVmean ratio, volume, and total lesion glycolysis (TLG) were determined for the spleen, liver, kidneys, lungs, and brain. Only SUVmean and SUVmean ratio were assessed for fat, bone, and skeletal muscle. Intercorrelations among all tissues and correlations with tumour TLG were calculated. Volume and uptake measures were compared between patients with and without progression using the Wilcoxon signed-rank test. Any measure significantly associated with two-year TTP was added to an existing logistic regression model based on baseline tumour characteristics to assess its added prognostic value. RESULTS: Patients with progression showed a significantly higher spleen-to-blood SUVmean ratio, lower SUVmean and TLG in the brain, lower SUVmean in skeletal muscle, and a larger liver volume. Liver volume and spleen-to-blood SUVmean ratio did not significantly improve the prediction of two-year TTP compared to the original model only based on tumour characteristics. CONCLUSION: Healthy tissue PET/CT measures were significantly associated with two-year TTP in DLBCL patients. However, these measures did not improve the prediction of two-year TTP compared to models using only tumour characteristics. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: HOVON-84: EudraCT: 2006-005, 174 - 42, retrospectively registered 01-08-2008.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Gerards NR, Wiegers SE, Bes AL, et al. Can we obtain prognostic information from healthy tissue uptake and volume in baseline 18F-FDG PET/CT imaging in diffuse large B-cell lymphoma? Eur J Nucl Med Mol Imaging. 2025. PMID: 40824452. doi:10.1007/s00259-025-07503-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。